GSK Advair Panel Review Will Focus On Single Survival Study
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is asking the Pulmonary-Allergy Drugs Advisory Committee whether results of GSK’s sole survival study are robust and what additional data would be needed for a survival claim.
You may also be interested in...
Advair Panel Denies Survival Benefit, But Endorses Other Efficacy Claims
FDA’s Pulmonary-Allergy Drugs Advisory Committee votes against evidence that GSK’s Advair increases survival, but agrees the combination product reduces exacerbations of COPD.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).